Lupin inks exclusive licensing agreement with US firm for biosimilar of its cancer drug

The product would be manufactured at Lupin’s biotech facility in Pune, which the USFDA had inspected prior to the approval, Lupin had said.

Leave a Reply

Your email address will not be published. Required fields are marked *